

## News Release

### Biofrontera AG announces results of its Annual General Meeting

**Leverkusen, Germany, July 13, 2018** –Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announced the voting results of its annual general meeting of shareholders (the “Meeting”) held on July 11, 2018. Shareholders representing 62,86% of the company’s registered share capital attended the Meeting.

The shareholders voted overwhelmingly in favor of all agenda items 2-5 of the company, as published in the German Federal Gazette on June 4, 2018, including the election of Mr. Eyring as a new member of the Supervisory Board. The shareholders, with a clear majority, rejected the additional agenda items 7-20 previously submitted by Deutsche Balaton AG. No vote was required on agenda items 1 and 6.

"I would like to thank our shareholders for their continued support and continuous trust," said Dr. Ulrich Granzer, Chairman of the Supervisory Board of Biofrontera AG, who chaired the Meeting. "On behalf of the Supervisory Board, I would like to congratulate Mr. Eyring on his election to our Board and look forward to working with him."

In their presentations, the Management Board members emphasized the successes on the regulatory side, the increasing product sales in Europe and the US as well as the improved visibility of the company in the US following its IPO on NASDAQ. "We have set ourselves the goal of rapidly growing the market potential of Ameluz<sup>®</sup> and our strategy of expanding the indications for Ameluz<sup>®</sup> is already showing initial success. The recent approval for daylight PDT in Europe as well as the US billing codes released in January now allow patients with actinic keratoses broad access to Ameluz<sup>®</sup>," said CEO Prof. Dr. Hermann Lübbert.

The company has published a detailed report of the voting results on its website at [www.biofrontera.com](http://www.biofrontera.com).

-End-

**For enquiries, please contact:**

**Biofrontera AG**

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0

ir@biofrontera.com

**IR UK: Seton Services**

Toni Vallen

+44(0) 20 7224 8468

**IR and PR US: The Ruth Group**

IR: Tram Bui

PR: Kirsten Thomas

+1 646-536-7035

+1 508-280-6592

**About Biofrontera:**

Biofrontera AG is an international biopharmaceutical company specializing in the development and commercialization of a platform of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Biofrontera's approved products focus on the treatment in the U.S. and Europe of actinic keratoses, which are skin lesions that can sometimes lead to skin cancer, as well as the treatment of certain forms of basal cell carcinoma in the European Union. American Depositary Shares representing Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under the symbol "BFRA", and Biofrontera's ordinary shares are listed in the Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also available at [www.biofrontera.com](http://www.biofrontera.com).

**Forward Looking Statements:**

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the public offering and the intended use of proceeds from the offering. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. Such forward-looking statements are based on the currently held beliefs and assumptions of the management of Biofrontera AG, which are expressed in good faith and, in their opinion, reasonable. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company, or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and other factors are set forth in the Registration Statement on Form F-1 filed with the SEC, including in the section "Risk Factors," and in future reports that we will file with the SEC. Given these risks, uncertainties and other factors, prospective investors are cautioned not to place undue reliance on these forward-looking statements. The Company does not undertake an obligation to update or revise any forward-looking statement.*

**Biofrontera AG**

Hemmelrather Weg 201 | D-51377 Leverkusen, Germany  
Phone: +49 214 87632-0 | Telefax: +49 214 87632-90  
[info@biofrontera.com](mailto:info@biofrontera.com) | [www.biofrontera.com](http://www.biofrontera.com)

Supervisory board: Dr. Ulrich Granzer (Chairman) | Jürgen Baumann (Vice-Chairman)  
Executive board: Prof. Dr. rer. nat. Hermann Lübbert (CEO)  
Christoph Dünwald (CCO) | Thomas Schaffer (CFO)  
**Commercial register:** Handelsregister Köln | **Register number:** HR B 49717 (AG)  
**VAT-identification number according to § 27 a UStG VAT act:** DE 812374102